Published 24 hours ago • loading... • Updated 24 hours ago

China's Sciwind is in talks to license weight-loss drug in US, CEO says

Summary

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's (NOVOb.CO), opens new tab top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June.

3 Articles

Reuters

Center

Exclusive: China's Sciwind is in talks to license weight-loss drug in US, CEO says

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters.

24 hours ago·United Kingdom

Read Full Article